Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Q Lacy

Showing results (41-50 of 142) with videos related to

Pageof 15
Sort By:
Bone Marrow Transplantation|October 12, 2010
Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006M A Gertz, M Q Lacy, A Dispenzieri, et al.
Bone Marrow Transplantation|September 12, 2012
Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosisM A Gertz, M Q Lacy, A Dispenzieri, et al.
Bone Marrow Transplantation|December 26, 2001
Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantationA Tefferi, S Kumar, R C Wolf, et al.
Bone Marrow Transplantation|August 22, 2002
Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host diseaseS Kumar, R C Wolf, M G Chen, et al.
Mayo Clinic Proceedings|September 20, 2000
Thalidomide in the treatment of relapsed multiple myelomaS V Rajkumar, R Fonseca, A Dispenzieri, et al.
Bone Marrow Transplantation|September 12, 2001
Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host diseaseS Kumar, M G Chen, D A Gastineau, et al.
Bone Marrow Transplantation|September 25, 2012
Second auto-SCT for treatment of relapsed multiple myelomaW I Gonsalves, M A Gertz, M Q Lacy, et al.
Blood Cancer Journal|July 30, 2016
Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimenS J Jacobus, S V Rajkumar, M Weiss, et al.
Bone Marrow Transplantation|March 12, 2008
Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCTS K Kumar, D Dingli, A Dispenzieri, et al.
Blood Cancer Journal|October 27, 2015
Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapyB Siontis, S Kumar, A Dispenzieri, et al.
Pageof 15

Showing results (41-50 of 142) with videos related to

Sort By:
Pageof 15
Bone Marrow Transplantation|October 12, 2010
Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006M A Gertz, M Q Lacy, A Dispenzieri, et al.
Bone Marrow Transplantation|September 12, 2012
Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosisM A Gertz, M Q Lacy, A Dispenzieri, et al.
Bone Marrow Transplantation|December 26, 2001
Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantationA Tefferi, S Kumar, R C Wolf, et al.
Bone Marrow Transplantation|August 22, 2002
Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host diseaseS Kumar, R C Wolf, M G Chen, et al.
Mayo Clinic Proceedings|September 20, 2000
Thalidomide in the treatment of relapsed multiple myelomaS V Rajkumar, R Fonseca, A Dispenzieri, et al.
Bone Marrow Transplantation|September 12, 2001
Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host diseaseS Kumar, M G Chen, D A Gastineau, et al.
Bone Marrow Transplantation|September 25, 2012
Second auto-SCT for treatment of relapsed multiple myelomaW I Gonsalves, M A Gertz, M Q Lacy, et al.
Blood Cancer Journal|July 30, 2016
Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimenS J Jacobus, S V Rajkumar, M Weiss, et al.
Bone Marrow Transplantation|March 12, 2008
Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCTS K Kumar, D Dingli, A Dispenzieri, et al.
Blood Cancer Journal|October 27, 2015
Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapyB Siontis, S Kumar, A Dispenzieri, et al.
Pageof 15